Adipose Immune Remodeling in Obesity: Mechanisms, Clinical Implications, and Therapeutic Perspectives

Abstract

Obesity is associated with profound alterations in adipose tissue immune cell composition and function, a process termed adipose immune remodeling. This dynamic interplay between immune cells and adipocytes contributes to chronic low-grade inflammation, insulin resistance, and the development of obesity-related comorbidities. Recent advances in immunometabolism have elucidated cellular and molecular mechanisms underlying immune remodeling in adipose tissue, highlighting new therapeutic targets for intervention. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical features, diagnosis, and management of adipose immune remodeling in obesity, with an emphasis on recent advances, guideline recommendations, and practical implications for clinicians.

Introduction

Obesity is a global health crisis, with prevalence rates rising sharply in both developed and developing countries. Its pathogenesis involves not only excess caloric intake and sedentary lifestyle but also complex immunometabolic disturbances within adipose tissue. Adipose immune remodeling refers to the dynamic alterations in immune cell populations and their phenotypes within fat depots, leading to a state of chronic, low-grade inflammation that underpins many of obesity’s metabolic and cardiovascular complications. Understanding these immune changes is critical for developing novel approaches to prevent, diagnose, and treat obesity and its sequelae.

Epidemiology / Disease Burden

According to the World Health Organization, the global prevalence of obesity has nearly tripled since 1975, with over 650 million adults classified as obese as of 2016. Obesity significantly increases the risk of type 2 diabetes, cardiovascular disease, fatty liver disease, certain cancers, and all-cause mortality. The chronic inflammatory milieu generated by adipose immune remodeling is a key driver of these comorbidities. Epidemiological studies reveal strong associations between markers of adipose inflammation—such as increased circulating pro-inflammatory cytokines—and adverse clinical outcomes. These findings underscore the importance of targeting adipose immune alterations in both prevention and management strategies.

Pathophysiology

In lean individuals, adipose tissue is characterized by an anti-inflammatory immune profile, dominated by M2-like macrophages, regulatory T cells (Tregs), and other cells that support tissue homeostasis. In obesity, adipocyte hypertrophy and death promote chemokine release and immune cell recruitment, shifting the balance toward pro-inflammatory M1-like macrophages, Th1 cells, cytotoxic T lymphocytes, and B cells. This immune remodeling is orchestrated by signals such as hypoxia, free fatty acids, and damage-associated molecular patterns (DAMPs). The resulting cytokine milieu—including TNF-α, IL-6, and MCP-1—drives insulin resistance, impairs adipogenesis, and propagates systemic inflammation. Recent research has also highlighted the roles of innate lymphoid cells, eosinophils, and dendritic cells in adipose tissue homeostasis and dysfunction.

Risk Factors

While excessive caloric intake and reduced physical activity remain the principal drivers of obesity, genetic, epigenetic, and environmental factors modulate the degree of adipose immune remodeling. Visceral adiposity, in particular, is associated with more pronounced immune changes and higher cardiometabolic risk. Other risk factors include aging, chronic stress, sleep deprivation, and exposure to obesogenic pollutants. Emerging data suggest that early-life exposures—such as maternal obesity or malnutrition—may epigenetically program adipose immune responses, predisposing individuals to later metabolic disease.

Clinical Features

Adipose immune remodeling itself is subclinical, but its metabolic consequences manifest as features of the metabolic syndrome: central obesity, dyslipidemia, glucose intolerance, hypertension, and non-alcoholic fatty liver disease. Systemic markers of inflammation—C-reactive protein (CRP), IL-6, and TNF-α—are elevated in obese individuals. In some cases, patients may present with obesity-related complications such as type 2 diabetes or cardiovascular events, both of which are linked to underlying adipose tissue inflammation.

Diagnosis

Diagnosis of adipose immune remodeling is primarily research-based and not yet part of routine clinical practice. However, various biomarkers—such as circulating adipokines (leptin, adiponectin), inflammatory cytokines, and chemokines—can provide indirect evidence of adipose inflammation. Advanced imaging techniques (e.g., MRI, PET-CT) and adipose tissue biopsies enable direct assessment of immune cell infiltration and phenotype in research settings. In clinical practice, a combination of anthropometric measures, metabolic parameters, and systemic inflammatory markers is used to assess the risk of obesity-related complications.

Treatment & Management

Lifestyle modification—comprising dietary intervention, increased physical activity, and behavioral therapy—remains the cornerstone of obesity management and can favorably modulate adipose immune remodeling. Weight loss has been shown to reduce pro-inflammatory immune cell infiltration and shift the balance toward regulatory phenotypes. Pharmacologic agents such as GLP-1 receptor agonists and SGLT2 inhibitors not only promote weight loss but also exhibit anti-inflammatory effects in adipose tissue. Bariatric surgery induces profound metabolic and immunological changes, including reduced adipose inflammation and improved insulin sensitivity. Management of comorbidities—such as diabetes, dyslipidemia, and hypertension—should be individualized based on guideline recommendations.

Recent Advances / Emerging Therapies

Recent research has identified novel immunomodulatory pathways in adipose tissue that represent promising therapeutic targets. Agents targeting the NLRP3 inflammasome, CCL2/CCR2 chemokine axis, or macrophage polarization are in preclinical and early clinical development. Modulation of the gut microbiome and its metabolites has also been shown to impact adipose immune remodeling. Cellular therapies, including adoptive transfer of regulatory T cells or engineered macrophages, are under investigation for their potential to restore adipose tissue homeostasis. Precision medicine approaches integrating genomics, metabolomics, and immunophenotyping may enable individualized interventions in the future.

Guideline Recommendations

International guidelines emphasize the importance of comprehensive obesity management, including lifestyle intervention, pharmacotherapy, and bariatric surgery where indicated. While current guidelines do not specifically address adipose immune remodeling, they recommend aggressive risk factor modification in patients with features of metabolic syndrome or established cardiovascular disease. Ongoing research may lead to future incorporation of immune-based therapies and biomarkers into clinical guidelines for obesity management.

Conclusion

Adipose immune remodeling is a central feature of obesity pathogenesis, linking excess adiposity to chronic inflammation and metabolic dysfunction. Advances in our understanding of immunometabolic interactions have revealed new diagnostic and therapeutic opportunities, though translation into clinical practice requires further research. Clinicians should remain informed about ongoing developments as precision medicine and immunomodulatory therapies evolve. Ultimately, integrated management strategies targeting both metabolic and immune pathways may hold the greatest promise for reducing the burden of obesity and its complications.